-
公开(公告)号：EP4011913A1
公开(公告)日：2022-06-15
申请号：EP21195522.4
申请日：2012-06-29
发明人： MIMOTO, Futa , KURAMOCHI, Taichi , IGAWA, Tomoyuki , KAWAZOE, Meiri , KATADA, Hitoshi , SHIRAIWA, Hirotake , KADONO, Shojiro
IPC分类号： C07K16/28 , C07K16/46 , C07K16/00 , C07K16/18 , C07K16/30 , C07K16/36 , A61K39/395 , C12N15/09
摘要： The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved Fc region function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or only the second polypeptide by conventional technology.
-
公开(公告)号：EP2857420A1
公开(公告)日：2015-04-08
申请号：EP13797450.7
申请日：2013-05-30
IPC分类号： C07K16/32 , A61K39/395 , A61P29/00 , A61P35/00 , C07K16/28 , C07K16/46 , G01N33/15 , G01N33/50 , G01N33/531 , C12N15/09
摘要： The present inventors discovered that the above-mentioned problems can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.
-
3.发明公开RETENTION OF ANTIGEN-BINDING MOLECULES IN BLOOD PLASMA AND METHOD FOR MODIFYING IMMUNOGENICITY 审中-公开保持抗原约束力的血浆及方法分子进行修饰免疫原性
公开(公告)号：EP2698431A1
公开(公告)日：2014-02-19
申请号：EP12764620.6
申请日：2012-03-30
发明人： IGAWA, Tomoyuki , MAEDA, Atsuhiko , HARAYA, Kenta , IWAYANAGI, Yuki , TACHIBANA, Tatsuhiko , MIMOTO, Futa , KURAMOCHI, Taichi , KATADA, Hitoshi , KADONO, Shojiro
CPC分类号： C07K16/00 , C07K2317/52 , C07K2317/71 , C07K2317/72 , C07K2317/94
摘要： The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fcγ receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.
-
公开(公告)号：EP3795215A1
公开(公告)日：2021-03-24
申请号：EP20196633.0
申请日：2013-05-30
IPC分类号： A61P29/00
摘要： The present inventors discovered that the above-mentioned problems can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.
-
公开(公告)号：EP3078744B1
公开(公告)日：2020-08-26
申请号：EP14867380.9
申请日：2014-12-04
-
公开(公告)号：EP2679681B1
公开(公告)日：2019-08-07
申请号：EP12749420.1
申请日：2012-02-24
IPC分类号： C07K16/00 , A61K39/395 , A61P35/00 , C07K16/28
-
公开(公告)号：EP2889377A1
公开(公告)日：2015-07-01
申请号：EP13831250.9
申请日：2013-08-23
IPC分类号： C12N15/09 , A61K39/395 , A61K47/42 , C07K16/28 , C07K19/00
摘要： An objective of the present invention is to provide an Fc region variant with enhanced FcγRIIb-binding activity, and/or enhanced binding selectivity to FcγRIIb compared to FcγRIIa (type R), as compared to those of a polypeptide containing an Fc region to which an amino acid alteration(s) has not been introduced; a polypeptide which includes the Fc region variant; a pharmaceutical composition containing the polypeptide; preventing therapeutic or preventive agent for immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method of enhancing FcγRIIb-binding activity and also enhancing binding selectivity to FcγRIIb compared to FcγRIIa (type R).
It was found that a polypeptide containing an antibody Fc region variant that contains an amino acid sequence in which an amino-acid alteration at position 238 (EU numbering) is combined with other specific amino-acid alterations enhances FcγRIIb-binding activity, and/or enhances binding selectivity to FcγRIIb compared to FcγRIIa (type R).-
公开(公告)号：EP4461751A2
公开(公告)日：2024-11-13
申请号：EP24187720.8
申请日：2014-11-11
IPC分类号： C07K16/42
摘要： The present inventors have successfully prepared an antigen-binding molecule comprising an antibody variable region that has binding activity against a molecule expressed on the surface of a T cell and a molecule expressed on the surface of any other immunocyte, but does not bind to these molecules at the same time. The present invention allows the preparation of an antigen-binding molecule capable of circumventing adverse reactions that may be caused by the cross-linking of T cells to other immunocytes, and provides an antigen-binding molecule suitable as a drug.
-
9.发明公开
公开(公告)号：EP3825325A2
公开(公告)日：2021-05-26
申请号：EP20194883.3
申请日：2012-03-30
发明人： IGAWA, Tomoyuki , MAEDA, Atsuhiko , HARAYA, Kenta , IWAYANAGI, Yuki , TACHIBANA, Tatsuhiko , MIMOTO, Futa , KURAMOCHI, Taichi , KATADA, Hitoshi , KADONO, Shojiro
IPC分类号： C07K16/00
摘要： The present invention demonstrated that the modification of the Fc region of an antigen-binding molecule into an Fc region that does not form in a neutral pH range a heterotetramer complex containing two molecules of FcRn and an active Fcy receptor improved the pharmacokinetics of the antigen-binding molecule and reduced the immune response to the antigen-binding molecule. The present invention also revealed methods for producing antigen-binding molecules having the properties described above, and successfully demonstrated that pharmaceutical compositions containing as an active ingredient such an antigen-binding molecule or an antigen-binding molecule produced by a production method of the present invention have excellent features over conventional antigen-binding molecules in that when administered, they exhibit improved pharmacokinetics and reduced in vivo immune response.
-
公开(公告)号：EP3604330A1
公开(公告)日：2020-02-05
申请号：EP19190090.1
申请日：2012-02-24
IPC分类号： C07K16/00 , A61K39/395 , A61P35/00 , C07K16/28
摘要： An objective of the present invention is to provide a polypeptide containing an Fc region having maintained or decreased binding activities towards both allotypes of FcγRIIa, types H and R, and having enhanced FcγRIIb-binding activity in comparison with a parent polypeptide; a pharmaceutical composition containing the polypeptide; an agent for treating or preventing immunological inflammatory diseases that includes the pharmaceutical composition; a production method thereof; and a method for maintaining or decreasing binding activities towards both allotypes of FcγRIIa and enhancing the FcγRIIb-binding activity. Specifically, it is found that a polypeptide containing an antibody Fc region that has an alteration of substituting Pro at position 238 (EU numbering) with Asp or Leu at position 328 (EU numbering) with Glu enhances FcγRIIb-binding activity, and maintains or decreases binding activities towards both allotypes of FcγRIIa, types H and R. It is also found that a polypeptide containing an antibody Fc region that contains an alteration of substituting Pro at position 238 (EU numbering) with Asp and several other alterations, enhances FcγRIIb-binding activity, and maintains or decreases binding activities towards both allotypes of FcγRIIa, types H and R.
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.031 秒)
